References
- Kvasnicka HM, Thiele J, Schmitt-Graeff A, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol 2001;19:2994–3009.
- Buesche G, Ganser A, Schlegelberger B, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007;21:2420–2427.
- Bueso-Ramos CE, Cortes J, Talpaz M, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004;101:332–336.
- Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99:381–383.
- Yamaguchi M, Munemoto S, Kasada A, et al. Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor. Leuk Res 2010;34:e237–239.
- Thiele J, Kvasnicka HM. Myelofibrosis—what’s in a name? Consensus on definition and EUMNET grading. Pathobiology 2007; 74:89–96.
- Hehlmann R, Moeller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014;32:415–423.
- Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011;1:e16.
- Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR–ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345–356.
- Gowin K, Emanuel R, Geyer H, et al. The new landscape of therapy for myelofibrosis. Curr Hematol Malig Rep 2013;8: 325–332.
- Inokuchi K, Yamaguchi H, Tamai H, et al. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib–resistant chronic myelogenous leukemia. J Clin Exp Hematop 2012;52:145–147.
- Hantschel O, Warsch W, Eckelhart E, et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 2012;8:285–293.
- Takeda Y, Nakaseko C, Tanaka H, et al. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. Br J Haematol 2011;153:589–598.
- Tanaka H, Takeuchi M, Takeda Y, et al. Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. Leukemia 2010;24:197–200.
- Bedekovics J, Kiss A, Beke L, et al. Platelet derived growth factor receptor-beta (PDGFRß) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis. Virchows Arch 2013;463:57–65.